Premium
SAFETY AND EARLY DATA FROM A PHASE II TRIAL OF PEMBROLIZUMAB (PEM) AND ENTINOSTAT (ENT) IN RELAPSED AND REFRACTORY (R/R) HODGKIN LYMPHOMA (HL) AND FOLLICULAR LYMPHOMA (FL)
Author(s) -
Sermer D.,
Vardhana S.,
Batlevi C.,
Hamilton A.,
Moskowitz A.,
Caron P.,
Moskowitz C.,
Matasar M.,
Biggar E.,
Leung E.,
Yahalom J.,
Rademaker J.,
Dogan A.,
Seshan V.,
Younes A.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.143_2630
Subject(s) - medicine , pembrolizumab , oncology , lymphoma , follicular lymphoma , gastroenterology , refractory (planetary science) , phases of clinical research , clinical trial , cancer , immunotherapy , physics , astrobiology